Please consider these data to be preliminary until they have been published in peer-reviewed journals.

Slides:

Advertisements

Similar presentations

FRISC II: Fragmin and fast Revascularization during InStability in Coronary artery disease - LONG-TERM HEPARIN - Purpose To assess efficacy of long-term.

Advertisements

FRagmin® and Fast Revascularization during InStablity in Coronary artery disease FRISC II.

The JUPITER Trial Reference Ridker PM. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–2207.

Fostering a Collaborative Approach in the Management of BRCA-Mutated Ovarian Cancer.

Current Management and Future Options for Tardive Dyskinesia

New Psoriasis Treatments

Highlights From the 2017 Annual European MS Meeting

Updates in the Clinical Science of CGRP Antagonism for the Treatment of Migraine.

Advances in Managing Inhibitors in Patients With Hemophilia A

Relapsed/Refractory Follicular Lymphoma Conundrums

Updates on CVOT Data and Clinical Comparisons That Matter

Progression After Cancer Immunotherapy in Advanced NSCLC

From the 2015 Conferences to the Clinic

Migraine Prevention Therapy: Avoiding Overuse of Medications

From Conference to the Clinic

Case Challenges in Chronic Migraine

Mid-Year Hemophilia Update

Induction Chemotherapy for Patients With High-Risk or Secondary AML

Insight Into the Latest Findings in Migraine

The Vicious Cycle of Chronic Migraine How Can the Physician Help?

Emerging Targeted Agents for Relapsed/Refractory Non-Hodgkin Lymphoma

The Nurse View.

Updates in Migraine From a 2018 American Headache Meeting

What Does the Primary Care Physician Need to Know About Chronic Hepatitis C?

Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS I)

Updates in Preventing Skeletal-Related Events in Multiple Myeloma

Diagnostic and Management Challenges in Patients With Chronic Migraine

Addressing Challenges in Factor VIII Inhibitors in Children With Hemophilia.

Management of CMV in HSCT Recipients

Evaluating Next-Generation BTK Inhibitors

Case Studies in Unresectable Hepatocellular Carcinoma

Targeting BTK Signaling in B-Cell Malignancies

Essential Concepts in the Use of Immunotherapies in Bladder Cancer

Ask the Experts.

Immunotherapy for cSCC

CGRP Antibodies in Migraine

Impactful Data in TD That Can Guide Treatment Decisions

How to Effectively Manage Patients With Cutaneous Squamous Cell Carcinoma.

New Data on Emerging Treatments for Psoriasis

Personalizing Management in the Care of Patients With Advanced Sarcoma

Breaking New Ground With Migraine Prevention Therapies

Expert Perspectives on the Clinical Use of Immune Reconstitution vs Escalation Therapy for MS.

Updates in the Management of Acute Promyelocytic Leukemia

Getting to Grips With the Science of CGRP and Migraine

Advances in Immunotherapy for Peanut Allergy

Expert Perspectives on New Data in Multiple Sclerosis From the 2018 European MS Meeting.

PARP Inhibitors.

Scientific Update.

New Strategies to Reduce HF Readmissions

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Defining the Clinical Value of Endpoints Used in Migraine Trials

Moving the Goal Post: Multidisciplinary Management of Advanced NSCLC

Evaluating BTK Inhibitors in CLL

The Psychiatrist's Role in Tardive Dyskinesia

Patient and Clinician Perspectives on Preventive Therapy for Migraine

New Trends in Treatment for Major Depressive Disorder

Why Opioid Withdrawal Syndrome Should Be on Your Radar

Managing CLL With BTK Inhibitors

Novel Concepts in the Management of RCC

Debates and Dilemmas, Part 1

Peanut Allergy Immunotherapy

Secondary Progressive Multiple Sclerosis: What Do We Know and Where Are We Heading?

Prioritizing Prevention of HPV-Related Disease

The Psychiatrist's Role in Tardive Dyskinesia

Peanut Allergy Immunotherapy

Addressing Cardiovascular Events:

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Immune Checkpoint Inhibitors in Lung Cancer

A New Era in Migraine Prevention

Presentation transcript:

Updates in the Management of Migraine From the Annual Neurology Meeting

Please consider these data to be preliminary until they have been published in peer-reviewed journals.

Acute Treatment of Episodic Migraine

The Effect of Light Color on Migraine

Direct Costs Associated With Migraine in the United States

Predictors of Healthcare Costs

Predictors of Healthcare Costs: Results

Management of Chronic Migraine

What Does TEV-48125 Teach Us About the Perception of Migraine Headache?

Factors Associated With Significant Reduction in MHDs

A Multicenter, Prospective, Single Arm, Open Label, Post-Market, Observational Study to Evaluate the Use of sTMS in Reduction of Migraine Headache (ESPOUSE Study)

Prevention of Migraine

Randomized, Double-Blind, Placebo-Controlled Trial of ALD403 in the Prevention of CM

Hepatic Safety of Galcanezumab in Patients With Migraine

Primary Results of the Screening and Double-Blind Treatment Phases of the ARISE Trial for the Prevention of EM

Comorbidities in Migraine

Migraine and ADHD in Children: Design

Migraine and ADHD in Children: RR and OR of Having ADHD

Migraine and the Risk of Incident Hypertension in Women: Study Design

Migraine and the Risk of Incident Hypertension in Women: Results

Epidemiology of Migraine in Men: Measurements

Epidemiology of Migraine in Men: Results

The Effect of Psychiatric Symptoms on Headache-Related Disability in Migraine: Study Design and Methods

The Effect of Psychiatric Symptoms on Headache-Related Disability in Migraine: Results

Abbreviations

Abbreviations (cont)